Stocks in Focus

KOREA ADVANCED MATERIALS Falls Over 5% Following Decision on 3 Billion Won Capital Increase [Featured Stock]

Shin Ha-yeon
2026-08-19 09:25:36
[Edaily Reporter Shin Ha-yeon ] PPI. INC(062970)is trading lower in early trading following news that the company has decided to conduct a public offering worth approximately 3 billion won.

According to MP Doctor on the 19th, as of 9:24 a.m., KOREA ADVANCED MATERIALS is trading at 2,365 won, down 5.21% from the previous trading day. During the session, the stock also fell as low as 2,285 won, an 8.42% drop from the previous close.
[This image was generated using AI technology.]

KOREA ADVANCED MATERIALS announced yesterday that it had decided to conduct a public offering worth approximately 3 billion won by issuing 1,298,701 common shares to raise funds for the acquisition of securities in other companies. The planned issue price is 2,310 won per share, and the expected amount to be raised is 2.99999 billion won.

Concerns over the dilution of existing shareholders’ stakes due to the issuance of new shares through the public offering, coupled with the fact that the proposed issue price was set below the previous day’s closing price (2,495 won), are believed to have weighed on investor sentiment.

The public subscription period will run from the 24th to the 25th, with the payment due date set for the 27th. The new shares are scheduled to be listed on the 11th of next month. The entire amount raised is expected to be used to acquire securities of other companies.

Economy

Corporation

IT·Science

Economy

NEXTBIOMEDICAL CO., LTD., Which Made Its Mark Globally with NexPowder, Named a “KOSDAQ Rising Star” for the Second Consecutive Year

#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
2026-08-19 10:02:44

Corporation

Celltrion, Buoyed by Direct Sales, Expands into Asia’s Pharm-Emerging Markets... Solidifies No. 1 Position and Prepares New Drugs

Celltrion(068270)Celltrion is strengthening its market dominance in Asia—a leading “Shinhung” (emerging pharmaceutical) market—by leveraging its unrivaled direct-to-market competitiveness. While its f…
2026-08-19 09:54:02

IT·Science

LGCHEM,LTD Begins Preclinical Trials for ‘GNV205,’ an Immunotherapy Drug Based on Genube Technology

# LGCHEM,LTD is set to begin preclinical research on “GNV205,” an antibody-cytokine fusion candidate acquired from the domestic biotech firm GenuV. The company plans to develop it as a next-gen…
2026-08-19 10:20:03